anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The present invention relates to generation of an exercise plan. In an embodiment of the present invention, a method for generating an exercise plan from a plurality of exercises for a user is proposed. Each exercise of the plurality of exercises is associated with a parameter for indicating the status of said each exercise of the plurality of exercises. The parameter may be set to different values. For example, the parameter may be set to a first value indicates that the associated exercise has not been selected to be part of the exercise plan; similarly, a second value indicates that the associated exercise has been selected to be part of the exercise plan; and a third value indicates that the associated exercise has been performed by the user. The method can comprise the steps of: a) initializing the parameter of each exercise of the plurality of exercises into the first value; b) selecting a subset of exercises from the plurality of exercises to generate the exercise plan and updating the parameter of each selected exercise in the plurality of exercises into the second value; and c) updating the exercise plan based on the user&#39;s performance resulting from the execution of the exercise plan and the parameter associated with each exercise of the plurality of exercises. With the proposed method, an exercise plan can be generated and updated conveniently. The invention also proposes a device for generating an exercise plan.
PURPOSE:To obtain a colorless and odorless hair growing agent, safe for the skin, having remarkable hair growing effects and effectively used at an extremely low concentration by using an aqueous solution of extracted ingredients from Euchema serra J. Agardh, Euchema muricatum Weber van Bosse and/or seaweeds belonging to the family Ceramiaceae of red algae. CONSTITUTION:A hair growing agent is obtained by extracting at least one seaweed selected from Euchema serra J. Agardh, Euchema muricatum Weber van Bosse and seaweeds belonging to the family Ceramiaceae of red algae with hot water at 80-100 deg.C for &gt;1hr and using the resultant aqueous solution of the extract as the hair growing agent. Seaweeds selected from the group of Ceramium tenerrimum Okamura, Ceramium paniculatum Okamura and Ceramium japonicum Okamura are especially preferably used as the seaweeds belonging to the family Ceramiaceae of the red algae. Since the aforementioned extract solution has tackiness, it stays on the skin of the head for a long period and exhibits sustained effects. If the aqueous solution of the extracted ingredients is used as a rinse after washing hair, effects, e.g. coming out of a hair dye liquor dyed on the skin and further sterilizing effects are exhibited. Since the extract solution is also edible, the hair growing agent is safe.
PURPOSE:To provide a dental adhesive set capable of simultaneously pretreating the enamel and dentine of teeth and of strongly adhering to both the parts. CONSTITUTION:The dental adhesive set comprises a preliminarily treating agent consisting mainly of an organic acid or its salt and water and having a pH of 0.8-2.2 and an adhesive composition containing 100 pts.wt. of a vinylic monomer containing &gt;=39wt.% of an acidic group-containing vinylic monomer of formula I (R1 is H, methyl; R2 is 1-20C organic residue; m is 2-4; n is 1, 2) and 0.1-3 pts.wt. of a polymerization initiator (especially the combination of a photosensitizer and a photopolymerization initiator is preferable from the view-point of adhesive strength). The vinylic monomer of formula I used herein is e.g. a compound of formula II. The organic carboxylic acid is preferably citraconic acid, lactic acid, 1,3,5-pentane tricarboxylic acid, tricarballylic acid, acrylic acid, or the like, especially because of exhibiting strong adhesive strength to dentines.
The invention discloses a natural antiseptic composition and a preparation method thereof. The composition is prepared from Arabic gum, hawthorn seed essential oil, grape seed essential oil, ginkgo essential oil, tea extract and water through emulsification. Sources of the composition are natural, so that the composition can meet consumers&#39; demand for natural health and can be applied to food and cosmetic products. The composition has a broad-spectrum bacteriostatic effect, can obviously inhibit bacteria, such as escherichia coli, staphylococcus aureus, bacillus subtilis, yeast and mould, and is good in bacteriostatic capability. The bacteriostatic effect can be achieved by adding 0.001-0.05% of the composition to food or cosmetics. The composition is low in application cost and stable in quality, can be saved for no less than three years at the room temperature, and is suitable for industrial production and application.
PURPOSE:To industrially and efficiently obtain a flaky barium sulfate provided with a particle property suitable for applications such as to pigments and cosmetics. CONSTITUTION:The crystal particle of the barium sulfate has &gt;=5 aspect ratio, &gt;=2mum average particle diameter in planar shape and is free from any exceptional projecting or recessed part on the peripheral part of the planar face, and the flaky barium sulfate is provided with the property revealing streamline by streamline evaluating method when the crystal particle is made into a water based slurry. The flaky barium sulfate is produced by adding a barium salt solution to a sulfate solution simultaneously in such a concn. and vol. ratio that the concn. of a formed slurry of barium sulfate is made &lt;=5wt.%, and the quantity of sulfate ion excessive to Ba ion in the system is set to 0.1-3g/l based on sulfate ion through the reaction process in this barium sulfate forming reaction by the barium salt solution and the sulfate solution.
PURPOSE: Provided is novel constructs and vectors for the targeted and inducible expression of genes. In particular novel hybridpromoters and their use for the expression of genes in hepatic cells, in vitro or in vivo. CONSTITUTION: A recombination vector, arranged under the regulation of promoter, comprises an expression cassette constituting nucleic acids coding a desirable protein and is enable to express genes inducibly by fibrate and selectively in a hepatic cell. A promoter comprises a regulator of human Apolipo protein AII(apoAII) gene. In particular, 3&#39;end and 5&#39; end thereof are located at between +5 and +35, preferably, +10 and +30, and between -950 and -905, preferably, -925 and -910 of apoAII gene residue respectively. The favorable recombination vector is a virus vector, especially, induced from adenovirus vector, comprising an expression cassette which is inserted into E4 region of the genome as a substitute for a deletion.
?927PP.APP(FF)                                             PATENT                Lawter &amp; Sherman Case 1 Combined with Hussain Case 1 CARRIER COMPOSITION AND METHOD                    Abstract of the Invention A composition and method of making it.  The composition includes a carrier and particles adhered to the carrier.  The particles include oil and water soluble matrix material.  The encapsulation material is water soluble.  The oil is encapsulated by the encapsulation material.  The carrier is substantially insoluble in the water.
A method  and  apparatus  for  tracking  with  a central  monitoring  system  status and result information associated with a plurality of test cards.   Each  of  the test  cards  is anonymously associated with a patient such that  the patient&#39;s identity is  unknown  to  the  central monitoring   system.   A  first  set  of  unique  personal identification numbers (PINs)  is  stored  in  a  personal identification  number  database in the central monitoring system, and a first digital signal representative of  PINs from  the  first  set of unique PINs is provided to a test kit assembler.  A second digital signal is received in the central  monitoring  system   from the test kit assembler. The second digital signal is representative of  test  kits actually  assembled.   Each  of  the  test  kits  actually assembled includes a test card having one  of  the  unique PINs   from  the  first  set  of  unique  PINs  associated therewith.  The first set of unique  PINs  is  tracked  by updating  the  personal  identification number database in response to the second digital signal.   A  third  digital signal is provided from the central monitoring system to a test lab. The third digital signal is representative of a second  set  of unique PINs and is provided by the central monitoring  system  in  response  to  the  second  digital signal. A fourth digital  signal  is  received  in the central monitoring system from the test lab.   The  fourth digital signal is representative of test cards received at the test lab  from  patients.   Each  of  the  test  cards received   at  the  test  lab  is  known  to  the  central monitoring system only by one of the unique PINs from  the first  set  of unique PINs, and the identities of patients associated with the test cards received at  the  test  lab are anonymous to the central monitoring system.  The first set of unique PINs is further  tracked  from  the  central monitoring  system by updating the personal identification number database and a test results database in response to the fourth digital signal.
Devices are provided for the controlled delivery of a therapeutic to a targeted location within a body. More particularly, devices are provided for controlling the rate of passage of an orally administered pill through a body, as well as for controlling the delivery of a therapeutic within the pill at a specific location within the body. Various types of devices, generally referred to herein as &#34;catchers,&#34; are provided that can actively catch a pill as it passes through a body. The catcher can hold the pill at a specific location within the body until a predetermined event occurs, such as partial or complete administration of a therapeutic within the pill. The catcher can then release the pill upon command and/or upon the occurrence of the predetermined event to allow the pill to pass out of the body. In other embodiments, various types of pills are provided that can actively engage a catcher and remain engaged with the catcher until a predetermined event occurs.
PURPOSE:A stable nicorandil tablet obtained by blending nicorandil with a specific saturated higher fatty acid or saturated higher alcohol. CONSTITUTION:A tablet obtained by blending a composition of nicorandil [N-(2- hydroxyethyl)nicotinamide nitrate] with &gt;=0.5wt% one or a mixture of two or more of saturated higher fatty acids, e.g. palmitic acid, stearic acid, etc., or saturated higher alcohols, e.g. cetyl alcohol, stearyl alcohol, etc., which are solid at ordinary temperature. The above-mentioned composition is prepared by blending nicorandil crystals with a pharmaceutical carrier, e.g. excipient, disintegrating agent, lubricant, colorant, binder, etc. The remedy has coronary vasodilator and coronary arterial contraction inhibitory action and is a remedy for various disease types of angina pectoris hardly affecting cardiac blood circulation kinetics and cardiac function. EFFECT:A step of coating the nicorandil crystals is not required.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide proteins usable in developing vaccines against Streptococcus agalactiae infections and Streptococcus pyogenes infections.  &lt;P&gt;SOLUTION: The proteins (including amino acid sequences and the corresponding nucleotide sequences) derived from Streptococcus group B (Streptococcus agalactiae) and Streptococcus group A (Streptococcus pyogenes) are provided. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibodies. The compositions are to be used for treating or preventing infections or diseases caused by Streptococcus bacteria, particularly Streptococcus agalactiae and Streptococcus pyogenes.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for efficiently extracting/collecting antioxidative components contained in cell walls through cutting the high molecular structure of plant cells with hydrolysis of a plant raw material under saturated vapor at heating temperature without using hot water in a subcritical water area.  &lt;P&gt;SOLUTION: This method for extracting/collecting the antioxidative components contained in cell walls comprises raw material charging treatment, hydrolyzing treatment and cooling treatment. The raw material charging treatment comprises charging a plant raw material containing the antioxidative components in cell walls into a treatment chamber and sealing the treatment chamber. The hydrolyzing treatment comprises heating the plant raw material in the treatment chamber at 130-150°C, and breaking the cell walls of the plant raw material through exposing the plant raw material for a fixed time in steam atmosphere of water contained in the plant raw material, and releasing the antioxidative components contained in cell walls from cell walls followed by taking into steam containing plant cell components taken out by destruction of cell walls. The cooling treatment comprises performing hydrolyzing treatment and extracting the antioxidative components contained in steam through cooling steam in the treatment chamber.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
A method and solution for perioperatively inhibiting a variety of pain, inflammation and smooth muscle spasm processes resulting from urologic procedures. The solution preferably includes multiple pain and inflammation inhibitory agents and spasm inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer&#39;s solution. The solution is introduced luminally to continuously irrigate a urologic structure during a urologic procedure for preemptive inhibition of pain and inflammation and smooth muscle spasm while avoiding undesirable side effects associated with oral, intramuscular, subcutaneous or intravenous application of larger doses of the agents. One preferred solution to inhibit pain, inflammation, and spasm includes a serotonin2 antagonist, a histamine1 antagonist, a cyclooxygenase inhibitor, a neurokinin2 antagonist, a purine2X antagonist, an ATP-sensitive K+ channel antagonist, a Ca2+ channel antagonist, one or more nitric oxide donors, a bradykinin1 antagonist and a bradykinin2 antagonist.A method and solution for perioperatively inhibiting a variety of pain and inflammation and spasm processes at a wound. The solution includes multiple pain and inflammation inhibitory agents and spasm inhibitory agents at dilute concentration in a physiologic base, such as saline or lactated Ringer&#39;s solution. Depending on the application, the pain and inflammation agents included in the solution may include: (1) serotonin receptor antagonists; (2) serotonin receptor agonists; (3) histamine receptor antagonists; (4) bradykinin receptor antagonists; (5) kallikrein inhibitors; (6) tachykinin receptor antagonists, including neurokinin1 and neurokinin2 receptor subtype antagonists; (7) calcitonin gene-related peptide (CGRP) receptor antagonists; (8) interleukin receptor antagonists.
PROBLEM TO BE SOLVED: To obtain an antiseptic for cosmetics capable of manifesting remarkably high antiseptic and bactericidal effects by using fine powder of a specific mineral and its action to enhance surface activities of water, alcohol, etc. SOLUTION: In this antiseptic for cosmetics, fine powder of a material called tourmaline is used. Tourmaline is a silicate mineral containing boron and belongs to a trigonal or a hexagonal hemimorphic hemihedral form which is asymmetric in above and below. Its chemical formula is complicated and the typical one is expressed by the formula (X is Mg, Fe, Li, etc.). Tourmaline is more excellent in chemical resistances against acids, alkalies, etc., than silica. Thus, when mixed in cosmetics, no chemical reaction occurs with the acids and the alkalies included in the cosmetic components. When tourmaline is brought into contact with water, it is electrolyzed by its action as permanent electrodes and has a function to emulsify and disperse an oil component in water as hydroxyl ions formed by the electrolysis which exhibit a surface activity.  The fine particles have preferably &lt;=10μm particle size.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a skin care preparation which is used for the skin and is obtained from an extract of Calanthe plants, Phaiusflavus(Blume) Lindl. plants, or other Orchidaceae plants having pseudo-bulbs or their juices.  &lt;P&gt;SOLUTION: Indican is obtained by washing the flowers, roots, stems, leaves, whole body or parts of an Orchidaceae plant, such as Calanthe plant, with water, finely cutting the washed materials with a cutter, extracting the obtained fine pieces with water or an alcohol compound, or compressing the fine pieces to obtain a juice, and then repeatedly fractionating and eluting the water extract or alcohol extract, the juice or an extract from the juice with a combination of various kinds of chromatography. The indican is, if necessary, mixed with auxiliary functional nutrients such as vitamins, humectants, and table salt to obtain a skin care preparation for external use, such as hair tonic, bleaching agent, humectant, or anti-dandruff bacterium agent. The indican is originated from the natural product, is therefore non-toxic and non-irritative, and is also effective as a skin care agent capable of being continuously used for a long period. The indican may, if necessary, be mixed with vitamins. The indican can be applied to hair tonic, bleaching agent, humectant, or anti-dandruff bacterium agent.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
PURPOSE:To improve the age stability of the titled preparation obtained by the polyethylene glycol (PEG) fractionation process and containing less than specific amount of PEG, by adding glucose to the titled preparation. CONSTITUTION:A gamma-globulin solution obtained by PEG (average molecular weight; 3,000-20,000) fractionation process is subjected to e.g. alcohol fractionation, salting-out or treatment with synthetic adsorbent to remove PEG and to obtain a gamma-globulin solution having a PEG concentration of &lt;=0.05% based on protein concentration of 5-20W/V%. The obtained solution is sterilized by conventional filtration process, added with 1-10% of glucose based on 5-20W/V% of protein, and freeze-dried to obtain a dried preparation. The preparation is divided into packaging units each containing 500-1,000mg of gamma-globulin. It is administered by intravenous injection after dissolving in distilled water for injection.
PURPOSE: To obtain a new compound useful as a medicine, having excellent activity against viruses. CONSTITUTION: This compound is shown by formula I (R is an alkenyl, a cycloalkyl, an aryl, etc.; R&lt;2&gt; is an aryl or a heterocyclic group; X is H or a halogen; A is N or CH) or its salt such as 1-(4-fluorophenyl)-7-(1H-imidazol-1- yl)-1,4-dihydro-4-oxoquinoline. The compound, for example, is obtained by reacting a compound of formula II (X&lt;2&gt; is Cl, Br, etc.) with a compound of the formula R&lt;2&gt; Sn(Alk)3 (Alk is a 1-6C alkyl) in the presence of silver oxide and a Pd catalyst such as tetrakis (triphenylphosphine)palladium. The reaction is usually carried out in an inert gas atmosphere at 50-170 deg.C for 1 minute to 24 hours. A compound of formula II is a new compound and, for example, is obtained by using a compound of formula III as a starting raw material.
PURPOSE: To facilitate the doctor&#39;s diagnosis by automatically specifying a lesion part from X-ray CT images. CONSTITUTION: The image obtd. by an X-ray CT apparatus 1 is stored into an original image storage memory 2. A blood vessel extracting section 12 extracts the blood vessel from this image. A number-of-pixel specifying section 14 segments the blood vessel to microregions along the blood vessel and determines the number of pixels constituting the blood vessels in the respective microregions. A lesion part specifying section 15 specifies the lesion part by investigating the change in the number of pixels within the respective microregions with respect to the row of the respective microregions along the blood vessel.  The normal blood vessel is finer from its base end toward its terminal and, therefore, the number of pixels in the respective microregions lining up in its direction changes gradually less but the tumor part made in the blood vessel bulges to a spherical shape and the change in the number of pixels from the normal blood vessel toward the tumor part increases without gradually lessening. The lesion part is specified by noticing such change in the number of pixels. The specified lesion part is displayed on a monitor 6.
This invention manages the variation of neuromodulation sequences inherent in effective treatment for poly-substance abuse and dependence through downloadable neuromodulation protocols for common poly-substance combinations. The substance abuse profiles and the poly-substance neuromodulation protocols are placed on an Internet connected server, allowing effective management of complex treatments via network-attached client software to addiction clinics in most of the geographic areas in the world. Such downloadable protocols may be selected based on the addict&#39;s presenting drugs, drug history (from the addict and from appropriate medical personnel), health deficits (e.g. compromised liver) and other factors. Modifications to the downloaded protocol may become desirable as acute withdrawal symptoms emerge or other new information regarding the patient&#39;s condition becomes available. The treatment protocol may be changed during the patient&#39;s treatment through the download of different protocols dynamically adjustable treatment parameters under control of the treatment provider.
A novel strain of lactic acid bacteria was found to be heat resistant and able to grow in a sulfur-limiting medium (SLM) containing a high concentration of sodium selenite. The microorganism is a non-spore forming and Gram-positive coccus, which is identified with &gt;90% confidence using the API biochemical and sugar fermentation tests, ribotyoing and 16S rRNA sequencing as  Pediococcus pentosaceus  SP80. In the current study,  P. pentosaceus  SP80 grown on SLM containing 250 ppm sodium selenite produced both organic and inorganic forms of selenium. These selenium compounds can be separated using an anion exchange chromatography technique. The concentrations of selenium detected in the organic and inorganic fractions were 4.34 and 21.7 ppm, respectively. Selenium-enriched bacteria are useful as a source of selenium for supplementing the diets of animals and humans. Animals fed efficacious amounts of the selenium-enriched bacteria show improved feed conversion rates and higher levels of glutathione peroxidase (GPx) activity in heart, kidney and liver tissues indicating an increased absorption and retention of selenium over control diets.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a physiologically active composition containing Sparassis crispa enabling the commercial supply of Sparassis crispa known to have usefulness.  &lt;P&gt;SOLUTION: Water is added to the powder produced by freeze-drying the fruit body of Sparassis crispa (product of Unitika Ltd.) and mixed with Cellulase Onozuka (product of Yakult Honsha Co., Ltd.) to effect enzymatic reaction. The reaction product is heated to 100°C and maintained for 5 min to deactivate the enzyme. The residue is separated by filtration and the extracted liquid is freeze-dried to obtain the enzymatic treatment product of Sparassis crispa. The physiologically active composition contains the enzymatic treatment product as an active component. The physiological activity is preferably antitumor activity, blood sugar level regulating activity, antihyperlipemic activity, antiallergic activity or antihypertension activity.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI